We describe the case ofa 37-year-old woman who experienced a painful thrombosis of an orbital venous malformation. We successfully treated her with surg ical decompression via a computer-assisted, endoscopic transethmoidal orbit otoniy. Removal of the lamin a papyracea and evacuation of the thrombus provided immediat e symptomati c relief Decompression via an endoscopic transethmoidal route provides a more direct and less invasive app roach than other techniques.
Introduction
Orbital venou s malform ations usually manifest as intermittent unilateral proptosis during the second or third decade of life. In most cases, management of these malformations is conservative and supportive. More aggressive intervention s-in the form of vascular clipping, cauterization, evacuation, or excision-is reserved for those lesions that threaten vision or cause severe pain.!" In this article, we report the case of a patient who required acute intervention for a painful thrombo sed orbital venous malformation.
Case report
A 37-year-old woman came to us with a 2-day history of positional right orbital pain and lower-eyelid ecchymosis. Her orbital discomfort increased with movement of the eye and during physical activity. She denied vision loss or diplopi a. Her medical history included a nasal fracture at 4 years of age and rhinoplasty at 19 years.
Examination revealed lower-eyelid ecchymosis and 1 mm of proptosi s on the right and bleph aropto sis bilaterally (figure 1). The patient' s visual acuity was 20120 in each eye. Her ocular motility was glob ally limited as a result of the orbital discomfort. The result s of pupillary, visual-field, slit-lamp, and ophthalmo scopic examinations were normal. Physical findings were unchanged with dependent head positioning and with Valsalva 's maneuver. Intran asal findings were normal.
The patient underwent computed tomo graphy (CT) and magnetic resonance imaging (MRI) (figure 2). CT showed a well-demarcated 2.0 x I.O-cm soft-tissue mass Axial-plane noncontrast CT shows a smooth, well-demarcated 2.0 x 1.0-cm sof t-tissue density in the right orbit. The elliptical mass lies along the right medial wall, displaces the medial rectus muscle, and does not contain calcifiedfoei. B: Coronal-plane noncontrast Tl-weighted MRI shows the mass positioned between the medial and inferior rectus muscles. The mass demonstrates a heterogenous signal intensity with a high signal center (arrowhead) and a low signal periphery. C: On coron al gadolinium-contrast Tl-weighted MRI, enhancement of only the adjacent rectus muscles is seen. D: Coronal T2weighted MRI shows that the core ofthe mass is markedly hypointense. The signal characteristics ofthis area are consistent with early (3 to 7 days ) subacute hemorrh age.
in the medi al right orbit. On MRI , the mass had a heterogenous signal intensity who se characteristics were con sistent with those of subacute hemorrhage and thrombosi s. The combined clinical and ima ging findings strongly supported a dia gno sis of a thrombosed orbital venou s malformation . Outpatient management with oral acet am inophen/oxycodone and restricted physical activity was prescribed.
Durin g re-evaluation 48 hour s later, the patient reported that conservativ e management had failed to control her pain. In view of this treatment failure , we offered surgical decompression of the malformation. We performed a computer-assisted orbitotomy via an endoscopic trans ethmoidal approach (figure 3). Remo val of Volume 81, Number 5 the lamina papy racea and evacuation of the orbital thrombus provided immediate symptomatic relief. Complete hemostasis was achie ved following the thrombu s evacuation. The patient's proptosis and dysmotility resolved immediately. At 18 month s of follow-up, her physical finding s remain normal.
Discussion
Prio r to the publication of the Orbital Society's 1999 recommendations,"orbit al venous malformations characterized by a low degree of vascular flow were broadly termed orbital varices. The nomenclature change was prec ipitated by a debate over the differentiation of orbital varice s from lymphangiomas. This was important given Figure 3 , Intraoperative endoscop ic transethmoidal views of the right orbit, A: Once the lamina papyracea has been removed, the dark-colored varix (arrows) is visualized in the infero nasal orbit through the intact periorbita . B: The per iorbita is stripped f rom the orbital sof t tissues and retracted in the lumen of the suction catheter. The dusky, intact varix is easily distinguishable fr om the surrounding orbitalf at. C: Af ter a sickle-shaped knife has incised the medial wall ofthe varix, the thrombus contained in its lumen is exposed. The clot will be removed in a piecemealfashio n with suction andf orceps. The varix wall will not be resected. D: The orbital f at expands to fi ll the void created by the completely evacuated varix. Note that there is no active hemorrhage from the lesion. that histopathologic confirmation of orbital varices is uncommon.
Two vascular features of orbital venou s malformations playa role in the lesion' s char acteristic appearance: (I) an absence of valves in the orbit al veins and (2) a low degree of intrinsic blood flow. The absence of valves allows for induced variability in venou s pressure, which promotes the physical expansion and deflation of the malformation. Thus , lowering the head position or performing Valsalva' s maneuver clinically precipitates intermittent proptosis.' ? A low degree of intrinsic blood flow through the malformation predi sposes it to intravascular thrombosis . When orbital venous malformations hemorrhage and/or thrombose, they produce sustained proptosis and pain .1·3
The diagnosis of orbit al venou s malformation is usually 348 not made histopathologically but rather by the clinic al picture and supportive imaging studies. The utilit y of multiple imaging modalities-including CT, MRI , sonograph y, venography , and color Doppler imaging-in the diagnosis of orbital venous malfo rm ations has been established.!" The advantages of MRI in this condition include not only its noninvasive nature but its ability to demon strate intralesional hemorrhage and thrombosis. MRI signal inten sities from a thrombus depend on the oxy genat ion and degradation of its contained hemoglobin.' The ring-like, layered MRI signal confi guration and the ju xtapositioning of a vein, as was seen in our patient, are characteristic of intravascular thrombosis.v' <" Although most orbital venous malformati ons are managed conservatively , intervention is indicated for those 
WARNING: The replacement of a systemic corticosteroid with a topical corticosteroid can be accompanied by signs of adrenal insufficiency.
In clinical trials, using the recommended dose, the overall incidence of adverse events was comparable to vehicle placebo. The most commonly reported adverse events, not necessarily drug related , were, for NASONEX' and vehicle placebo, respectively: headache (17-26% vs 18-22%), viral infection (8-14% vs 9-11%), pharyngitis (10-12% vs 10%), epistaxis/blood-tinged mucus (8-11% vs 6-9%), and coughing (7-13% vs 6-15%). Seven hundred and twenty(720) patienls 310 11years ofage were treated wil h momelasone furoatenasal spray, 50meg (100 meg lolal daily dose) in controlled cli nical tri als. Safety and effecliveness inchildren less than 3years of age have not beeneslablished.
Aclinical sludy has been conducted for1 year in pediatnc patienls (ages 3109years) 10assess the elfect of NASONEX Nasal Spray, 50meg (100 meg tolal da ilydose) ongrowth velocity. No sla listically significanl effecl ongrowth vel oc~was observed forNASONEX Nasal Spray, 50meg compared 1 0place-
bo. Noevidence ofclinically relevantHPAaxis suppression was observed fol-lowinga3O-minute Cosyntropin infusion.
Thepotential otNASONEX Nasal Spray, 50meg tocause growth suppression insusceptible patientsorwhen givenathigherdosescannot be ruled out.
G er i a~i c Use: A total of203 palients ge 6410 B5 years) have beent . up 103 monlhs. in type andincidence tothose reporte dbyyounger patients. AOVERSEREACTIONS Inconlrolled US and Intemational clinical studies, a totalof3210adun and adolescent palienls ages 12years an d older received Ireatment vnthNASONEX Nasal Spray, 50meg atdoses of5010 800 meg/day. The majonty ofpatients (n =2103) were trealed with 200 meg/day. In con-Irolled USan dInternalional studies, atolal of 990 pediatrc patienls (ages 310 11 years) received treatmenlwith NASONEX Nasal Spray, 50meg,atdoses of 25to200 meg/day. ThemajoOty ofpedialnc patents (720) were ireated wil h 100 meg/day.Atotal of513adull ,adolescenl, an dpedaincpalienls have been treated for 1yearorlonger .The overall incidence ofadverse events forpatients treatedw~h NASONEX Nasal Spray, 50meg was comparable10patients treated with thevehicle placebo. .oJso, adverse events did notdiffer significanlly based on age, sex, orrace.Three percentorlessofpatientsinclinical trialsdiscontinued treatment because ofadverse events; this rate was similar for the vehicle and active comparaiors.
,AJI adverse events (regardless ofrelalionship totrealmenl) reported by5% ormoreofad u~and adolescent patientsages 12years and olderwho received NASONEX Nasal Spmy, 50meg, 200 meg/day and by pediatricpatientsages 31011years who rece"edNASONEX Nasal Spray, 50meg, 100 meg/ day in cl inical trials vs placebo and that were more common with NASONEX Nasal Spray, 50megthan placebo, are displayedinthe Iable below.
ADVERSE EVENTS FROM CONTROLLEOCLINICAL TRIALS INSEASONALALLERGIC ANO PERENNIALALLERGIC RHI NITIS (PERCENT OF PATIENTSREPORTINGj
Other adverseevents which occurredinless than5%but greater thanor equal to 2% of momelasone furoale adull and adolescent patents (ages 12years andolder) trealedwi lh2oo-mcgdoses(regardless ofrelationship to treatment),andmore frequentlythan inthe placebogroup included:arthralgia, asthma, bronchhis, chest pain,conjunctivitis, diarrhea, dyspepsia, earache, fl u-like symptoms, myalgia, nausea, and rhinitis.
Other adverse events whichoccurredinless than 5%butgreater thanor equal 102%01 momelasone fur oatepedialncpatients ages 3to11years treat-edVĨ h 1OO-mcg dosesvs placebo (regardless of relalionship 10 Irealment) andmorefrequenllythan inthe placebo groupincluded:diarrhea, nasal i r r~ tion, otitismedia, andwheezing. Rare cases ofnasal ulcers andnasal andoral candidiasiswere also reportedinpatientstreated wi lhNASONEX Nasal Spray,50meg,primanlyinpalienls trealedfor longer than4 weeks.
In postmarketing surveillance of Ihis product, cases of nasal burni ng and irritation,anaphylaxis and angioedema,and rare cases ofnasal septal perforationhave beenreported. OVEROOSAGE There are nodata available ontheeffects of acute orchronic overdosage w~h NASONEX Nasal Spray, 50meg. Beca use of low systemic bi oa va i l a bi l~, and an absence of acute drug-relaled systemic findings in cli nical studies, overdose isunlikely torequire any therapy other thanobservation. Intranasal administmt ion of1600 meg (8times the recommended dose otNASONEX Nasal Spmy, 50meg) dailyfor29days, toheallhy humanvolunteers,was welltoleratedwithno increasedincidence ofadverse events. Single intranasal doses up to 4000 meg have beenstudiedin humanvolunteers with noadverse effects reported.Single oral dosesup10Booo meg have beenstudied inhuman volunteers with no adverse effects reported. Chronic overdosage w~h any corticosteroid may result in si gns or symptoms of hypercorticism (see PRECAUTIONS).Acule overdosage VI~h Ihisdosage formisunlikelysince one bonleof NASONEX Nasal Spray, 50meg conlains approximalely 8500 mcg ofmometasone furoate.
Copynghl © 1997, 199B, 1999,Schenng Corporalion. All nghtsreserved. one single-dose, pamllel-group study otpatents inanouldoor "park"sefting (park study) and one environmenlal exposure un~(EE U)sludy and within 2daysafter the firstdose in~' IO randomized,double-blind, placebo-controlled, parall el-groupseasonal allergic rhinitis studies. Maximum benefit isusually achieved within 1to2weeks after init iati onofdosing. Patients shouldtake the medicationas directed and should not increase the prescribed dosage by using itmore than once a day in an attempt toincrease its effectiveness. Patients should contact their physician Hsymptoms do not improve, orif the condition worsens. To assure proper use of this nasal spray, and to attain maximum benefil, patients shouldread andfollow Ihe accompan0ng Patient's InstructionsforUsecarefully.
Adull andAdolescenlPatients
Pati entsshould be cautioned not tospray NASONEX Nasal Spray, 50meg into the eyes ordirectly onto the nasal septum.
Personswho are on immunosuppressant doses ofcorticosteroids should be warned toavoidexposure tochickenpox ormeasles, andpatients shouldalso be advised Ihal dthey are exposed, medica l advice should be sought w~hout delay.
Carcinogenesi s, Mutagenesis, Im pairmentof Fertility:Ina2-yearcarcinogenicity study ofSprague Dawleyrats, mometasonefuroatedemostratedno slal ist ically significant increase oflumorsatinhalaliondosesup10 67mcgikg (approximalely 3 and 2 times the maximum recommended daily inlranasal dose inadults and children, respectively, onamcg/m' basis). Ina19-monlh carcinogenicity study ofSwiss CD-1mice,mometasone furoate demonstrated no statistically significant increase inthe inci dence oftumors atinhalation doses upto160 mcgikg (approximately 4an d3 limes the maximumrecommended daily intranasal dose inadulls and children, respectively, onamcg/m' basis).
At cytotoxic doses, mometasone furoateproducedan increase in chromosome aberrations invitro inChinese hamster ovary-eell c u~u res inthe nonactivation phase, butnot inthepresence ofrat liverS9 fraction. Mometasone furoafe was not mulagenic in Ihe mouse-lymphoma assay and the Salmonel/aIE. cofVmammalian microsome mutation assay, aChinese hamster lung cell(CHl) chromosomal-aberrations assay, an invivomouse bone-marrow erythrocyte-m icronucleus assay, arat bone-marrow clastogenicity assay, and the mouse male germ-eell clastogenicity assay. Mometasone furoate also did notinduce unscheduledDNAsynlhesis invivo inrat hepatocytes.
In reproduclive sludies inrais, impairment of fertility was notproduced by subculaneous doses upto15mcgikg (less thanIhemaximumrecommended daily intranasal doseinadults on a mcglrrr basis). However, mometa sone furoale caused prol onged geslation, prolonged and difficull labor, reduced offspnng survival, and reduced maternal body weighl gain at a dose of 15 mcgikg.
Pregnan cy: Teratogenic Effec ts: Pregnancy Category C: Momelasone turoalecaused cleft palaie in mice atsubculaneous doses of60mcgikgan d above (approximately 2 times the maximumrecommended daily intranasal dose in adults ona mcg/m' basis) . Offspnngsurvival was reduced in the 1eo mcgikggroup(approximalely 4limes the maximumrecommendedda ily intranasal doseinadults on amcglm l basis). No such effects were observed at20mcgikg (less than the maximumrecommended dailyinl mnasal dose in adulls onamcg/m' basis).
Inrabbits, mometasone furoatecaused flexed fronl paws atatopical dermal dose of 150 mcgik g (approximalely 14times the max imum recommended dailyinlranasal dose inadultsonamcg/m' basis).
In rats, mometa sone furoate produced umbilical hernia, cleft palate, and delayed ossification at atopical dermal dose of 600 mcgikg (approximately 30ti mes the maximum recommended daily intranasal dose in a du~s on a mcg/m' basis). At 1200 mcgikg (approximalely 60 limes the maximum recommended daily int ranasal dose in adultsona mcglm' basis), microphthalmia, umbilical hernias, and delayedossificationwere observed in ratpups. Inthese developmenta lstudies, there were also reduct ionsinmaternalbody weighlgain and effects on felal grovrt h (lower felal bod y weights and/or delayed ossification)inmi ce (60 and180mcgikg), rabbits (150mcgikg), and rats (6oo mcgikg).
Inanoral developmenlalsludy inrabbits, at700mcgikg, (approximalely 70 timesthe maximum recommended daily intranasal dosein adults on amcgl mb asis), increased incidencesof resorptions and malformations, including cleft palale and/or head malformations (hydrocephaly or domed head) were observed. Pregnancyfai lure was observed in mosl rabbits at2BOO mcgikg (approximalely 270 times Ihemax imum recommendeddailyinlmnasal dose in adulls onamcgl m' bass).
There are no adequate and well-eontrolled studies in pregnantwomen. NASONEX Nasal Spray, 50 meg, like other corticosteroids, should be used durin g pregnancy only if the potenlial benefits justifyIhepo lential rtsk tothe fetus. Experience Vĩh oral corticosteroids since their introduction inpharmacologi c, asopposed to physiologic, doses suggests Ihal rodents are more prone toteratogenic effects fromcorticosteroids than humans. In addition, becausethere isa natural increase incorticosteroid productionduring pregnancy, most women will requirealowerexogenous corticosteroiddose and many will not needcorticosteroidtreatment during pregnancy.
Non teratogenic Effects: Hy poadrenalism may occur in infants bom to women receiving corticosteroids during pregnancy. Such infants shouldbe carefully monitored.
Nursing Molhers: It is not known ifmometa sone furoate isexcreted in human milk. Because other corticosteroids are excreted in hum an milk, caution shouldbe usedwhenNASONEX Nasal Spray, 50meg isadm inistered tonursingwomen.
Pediatric Use: Controlled clinical studies have shown intranasal corticosteroids may cause areductionin growth velocity inpediatri c pati ents. This effect has beenobserved inthe absence oflaboraforyevidence othypothalam i c -p~u~ry-adrenal (HPA) ax issuppression, suggestingthat growlhvelocity isamoresensnve indicator ofsystemic corticosteroidexposure in pediatric patientsthansome commonly usedtests ofHPAaxis functi on. The long-term effects ofthis reductioningrowthvelocity associated withintranasal corticosteroids, includingthe impactonfinal adult height,are unknown.The polential for "catchup" growth followingdisconti nuationoftreatment withintranasal corticosteroidshas not been adequalely studied. The growl h of pedial nc patients receiving intranasal corticosteroids, including NASONEX Nasal Spray, 50meg shouldbemon~ored routinely(eg,via sladiomelry). The polen-tialgro\ 'h effects ofprolonged Ireatmenl should be weighed againsl clinical benefits obtained and the availability ofsafe and effective no ncorticosteroid treatment a~emati ves.
Tominimize the systemic effects of intranasal corticosteroids; including NASONEX Nasal Spray, 50 meg, each patienl should be litratedtohislherlowesteffective dose.
NASONEX® (mometasone furoate monohydrate)
Nasal Spray, 50 mcg*
FOR INTRANASAL USE ONLY
•calculated ontheanhydrousbasis BRI EF SUMMARY (For full Prescnbing Informalion, see package insert.) INDICATIONSANO USAGE NASONEX Nasal Spmy, 50meg isindicaled for thetreatment ofthe nasalsymptoms ofseasonalallergicand perennial allergic rhi n~i s, inadultsand pediatnc pa tients 3 years ofage and older. NASONEX Nasal Spmy,50meg isindicaled torIhe prophylaxis ofIhe nasal symploms ot seasonal allergic rhinit isin adult and adolescent patients 12years and older.In patients \"tha known seasonal allergen that prec i p~fes nasal symptoms of seasonal allergic rhi n~i s , ini tiafion ofprophylaxis w~h NASONEX Nasal Spmy, 50meg isrecommended 2to4weeks pnor 10 the anticipated start ofIhepollen season.Satety and effectiveness otNASONEX NasalSpmy,50meg inpedialnc patients less Ihan 3years ofage have not beeneslablished. Personswho are ondrugs which suppress the immune system are more susceptible 10 infections than heallhyindividuals. Chickenpox and measles, for example, can have amor eserious orevenfatal course innonimmune children oradults oncorticosteroids.Insuch chi ldren oradults who have notha dthese diseases, particularcare shouldbe taken toavoidexposure. Howthe dose, route, anddurationofcorticosteroid administration affects the risk ofdevelopingadisseminated inf ectionisnot known. Thecontribution ofthe undertying disease and/or prior corticosteroidtreatment tothe risk isalso not known. If exposed to chickenpox, prophyl ax is with varicella zost erimmune globin (\'ZIG) may be indicated. If exposed tomeasles, prophylaxiswith pooled intramuscular immunoglobulin(IG) maybeindicated. (See therespeclive package inserts for complete VlIG and IG prescnbing intormation.) If chickenpox develops, treatment with antiviral agents may be considered. PRECAUTIONS General : Intranasal corticosteroids maycause areduction in growth velocitywhen administered topediatrl c pat ients(see PRECAUTIO NS, PediatricUsesection).Inclinical studies wilh NASONEX NasalSpray, 50meg, the developmenl oflocalized infecti onsofthenose an dpharynx with candida aibicans has occurred only rarely. When such an infeclion devel ops, use ot NASONEX Nasal Spray, 50meg should be discontinuedandappropriate local or syslemiclherapyinstiluled, if needed.
CONTRAINDICATIO NS
Nasal corticosteroids should beused with caution, ifataU, inpatientswith active orquiescent tuberculous infectionofthe respiratory tract, orinuntreatedfungal, bacterial,systemic viral infect ions, orocularherpes simplex.
Rar ely , immediatehypersensitivity reactions may occurafterthe intranasal administration ofmometasone furoatemonohydrate. Extreme rare instances ofwheeong have been reported.
Rare insta ncesofnasal septumperforation and increased intraocular pressure have also beenreportedfollowing theintranasalapplication ofaerosolized corticosteroids. As with any long-Ier mlopical treatmenl ofthe nasal cavity, patents usingNASONEX Nasal Spray, 50meg over several monlhs orlonger shouldbeexamined penodica llyforpossible changes inIhe nasal mucosa.
Becauseofthe inhibitory effect ofcorticosteroids onwound healing,patients who have experienced recentnasal septum ulcers, nasal surgery,ornasaltrauma shouldnot use anasal corticosteroid untilhealinghasoccurred.
Glaucoma andcataract formation was evaluated inone controlled study of 12weeks' dumtion and one unconlrolled sludy of 12 months' duration in patientstrealed with NASONEX Nasal Spray, 50meg at200 meg/ day, using intraocular pressure measurementsandslit lampexamination. No significant change frombaseli newas noted in the mean intraocular pressure measurements forIhe141 NASONEX-Ireated patients inIhe12-week studY, ascompared wi th 141 placebo-Irealed patienls. No individual NASONEX-trealed patientwas notedtohave developedasignificant elevation inintraocularpressure orcataracts inthis 12-weekstudy. Likewise, no significant change from baseline was notedinthe mean intraocular pressuremeasur ements for the 139NASONEX-trealedpatientsinthe 12-monlhstudy an dagain, nocataracts were detected in these patients.Nonetheless,nasal andinhaledcorticosteroids have been associafed w~h the developmenl of glaucoma and/or calaracts. Therefore, close follow-upiswarrantedin patients withachange invisionand with ahistory ofglaucomaand/or cataracts.
When nasal corticosteroids areused atexcessive doses, systemic corticosteroid effects suchas hypercorticism andadrenal suppression may appear.If suchchanges occur,NASONEX Nasal Spray, 50meg shouldbe discontinued slowly, consistent with accepted procedur es for discontinuing oral steroid Iherapy.
Infor mal ionforPatien ts: Patientsbeing trealed with NASONEX Nasal Spray, 50meg should begiven Ihefollowinginformationand inslruct ions.Thisinformation isintendedtoai dinthe safe andeffective use ofthismedication. It is notadisclosure ofallintended orpossible adverse effects.Patients should use NASONEX Nasal Spray, 50meg alregular inlervals(once daily)since itseffectiveness depends on regular use. Improvement in nasal symptoms ofanergic rhinitis has beenshown to occur \ 't hi n 11hours after the first dose based on ENDOSCOPIC TRANS ETHMOI DAL DEC OMPRESSION O F A THRO MB OSED ORBITAL VENOU S MALFORMATI ON th at ca use intractabl e pain and for those that threaten visio n. Modern surgical instrume ntatio n and techniqu e have ex panded the role of en doscopic surg ery . Selected lesion s of the medi al orbit ha ve been show n to be amenabl e to endoscopic transethmoidal diagnostic and ther apeuti c procedures.v'? The pro ximity of our patien t's malformatio n to the med ial orbital wa ll and the presen ce of a large intralesion al thro mbu s suggested that the malformation co uld be safe ly decompressed into the ethmo id sinu ses. We fo und the endoscop ic transeth moid al approach to be more dir ect and less invasive than previou sly described techniques.
